Hong, D. S. (2018). Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. The American Association for Cancer Research (AACR).
Chicago Style (17th ed.) CitationHong, D. S. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. The American Association for Cancer Research (AACR), 2018.
MLA (9th ed.) CitationHong, D. S. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. The American Association for Cancer Research (AACR), 2018.
Warning: These citations may not always be 100% accurate.